Projects per year
Personal profile
Personal profile
Dr. Cesar Arias has over 25 years of experience in the field of antimicrobial resistance. His career has focused on the clinical and molecular aspects of antimicrobial resistance (AMR) with emphasis on gram-positive organisms. He became interested in infectious disease (ID) because of its prominence as a public health problem and also because ID spans all aspects of clinical medicine. After medical school, he attended the University of London where he focused on clinical microbiology and performed research on the molecular biology of capsule genes in S. pneumoniae, developing molecular tools for capsule typing of this important pathogen. He obtained his PhD at Cambridge in 2000, studying the molecular mechanisms of vancomycin resistance in enterococci. During graduate studies, he discovered a new enzyme and elucidated a novel mechanism for synthesis of D-serine in bacteria. After completing residency at UTHealth McGovern Medical School as well as a fellowship in ID (joint program with UT MD Anderson Cancer Center), he expanded studies on staphylococci and enterococci.
He was the recipient of a K99/R00 NIH Pathway to Independence Award and now holds an NIH K24 mid-career investigator award to increase patient-oriented and mentoring activities on antimicrobial resistance. He has also founded two overseas research units (Molecular Genetics and Antimicrobial Resistance Unit and the International Center for Microbial Genomics) focused on AMR at Universidad El Bosque, Bogota, Colombia. His most recent research has concentrated on elucidating the mechanistic basis of resistance to daptomycin with focus on enterococci and to dissect the molecular epidemiology and clinical impact of multidrug-resistant organisms as part of the NIH-funded Antimicrobial Resistance Leadership Group. A major component of the research on MDR organisms is the use of genomics as a major tool to dissect the molecular epidemiology and population structure of MDR bacteria.
External positions
Professor of Medicine, Weill Cornell Medical College
Oct 1 2022 → …
Research Area Keywords
- Infectious Disease & Pathology
Fingerprint
- 1 Similar Profiles
Network
-
POR and Training Program on Multidrug-Resistant Organisms
7/1/22 → 6/30/26
Project: Federal Funding Agencies
-
VENOUS: A translational study of enterococcal bacteremia
6/1/22 → 5/31/25
Project: Federal Funding Agencies
-
The LiaFSR system and antimicrobial peptide resistance in enterococci
2/1/22 → 6/30/23
Project: Federal Funding Agencies
-
Dynamics of Colonization and Infection by Multidrug-resistant Pathogens in Immunocompromised and Critically Ill Patients (DYNAMITE)
9/1/21 → 7/31/25
Project: Federal Funding Agencies
-
-
A Case of successful treatment of recurrent urinary tract infection by extended-spectrum β-lactamase producing klebsiella pneumoniae using oral lyophilized fecal microbiota transplant
Bier, N., Hanson, B., Jiang, Z. D., Dupont, H. L., Arias, C. A. & Miller, W. R., Jan 1 2023, In: Microbial Drug Resistance. 29, 1, p. 34-38 5 p.Research output: Contribution to journal › Article › peer-review
-
Clinical and Molecular Analyses of Recurrent Gram-Negative Bloodstream Infections
Bock, A., Hanson, B. M., Ruffin, F., Parsons, J. B., Park, L. P., Sharma-Kuinkel, B., Mohnasky, M., Arias, C. A., Fowler, V. G. & Thaden, J. T., Feb 1 2023, In: Clinical Infectious Diseases. 76, 3, p. E1285-E1293Research output: Contribution to journal › Article › peer-review
-
Enolpyruvate transferase MurAAA149E, identified during adaptation of Enterococcus faecium to daptomycin, increases stability of MurAA–MurG interaction
Zhou, Y., Utama, B., Pratap, S., Supandy, A., Song, X., Tran, T. T., Mehta, H. H., Arias, C. A. & Shamoo, Y., Mar 2023, In: Journal of Biological Chemistry. 299, 3, 102912.Research output: Contribution to journal › Article › peer-review
Open Access -
Global epidemiology and clinical outcomes of carbapenem-resistant Pseudomonas aeruginosa and associated carbapenemases (POP): a prospective cohort study
Antibacterial Resistance Leadership Group and Multi-Drug Resistant Organism Network Investigators, Mar 2023, In: The Lancet Microbe. 4, 3, p. e159-e170Research output: Contribution to journal › Article › peer-review
Open Access1 Scopus citations -
International Multicenter Study Comparing COVID-19 in Patients With Cancer to Patients Without Cancer: Impact of Risk Factors and Treatment Modalities on Survivorship
Data-Driven Determinants for COVID-19 Oncology Discovery Effort (D3CODE) Team, Jan 2023, In: eLife. 12, e81127.Research output: Contribution to journal › Article › peer-review
Open Access